Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: Results from a large population-based follow-up study

Diabetologia

Volumn 55, Issue 1, 2012, Pages 51-62

  Ruiter, R ^a,b   Visser, L E ^a   Vn Herk Sukel, M P P ^c   Coebergh, J W W ^a   Haak, H R ^d   Geelhoed Duijvestijn, P H ^e   Straus, S M J M ^a,f   Herings, R M C ^a,c   Stricker, B H Ch ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Drug Safety Unit   (Netherlands)

^c PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^d MÁXIMA MEDICAL CENTER   (Netherlands)

^e MEDICAL CENTER HAAGLANDEN   (Netherlands)

^f MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

Breast cancer; Cancer; Insulin; Insulin analogues; Insulin glargine

Indexed keywords

HUMAN INSULIN; INSULIN GLARGINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY TRACT CANCER; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME;

BREAST NEOPLASMS; COHORT STUDIES; COMMUNITY PHARMACY SERVICES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; INSULIN, LONG-ACTING; INSULIN, REGULAR, HUMAN; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; NEOPLASMS; NETHERLANDS; PATIENT ADMISSION; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 84856715759     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2312-4     Document Type: Article

References (47)

1. Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J (2008) Harrison's principles of internal medicine, 17th edition. McGraw-Hill, New York
2. Collaboration Emerging Risk Factors, Sarwar N, Gao P et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215-2222
3. Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679-1687 (Pubitemid 41672234)
4. Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33:1674-1685
5. Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856-862 (Pubitemid 47106217)
6. Friberg E, Orsini N, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50:1365-1374 (Pubitemid 46879010)
7. Hassan MM, Curley SA, Li D et al (2010) Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116:1938-1946
8. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076-2083 (Pubitemid 40897433)
9. Larsson SC, Orsini N, Brismar K, Wolk A (2006) Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49:2819-2823 (Pubitemid 44730282)
10. Bonovas S, Filioussi K, Tsantes A (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47:1071-1078 (Pubitemid 38918167)
11. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160-1167 (Pubitemid 38747263)
12. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR (2007) Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 120:1986-1992 (Pubitemid 46418378)
13. Grote VA, Becker S, Kaaks R (2010) Diabetes mellitus type 2-an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 118:4-8
14. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16:1103-1123
15. Yang YX, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044-1050 (Pubitemid 39345873)
16. Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755-1765, Erratum 52: 2469
17. Currie CJ, Poole CD, Gale EA (2009) The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
18. Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732-1744
19. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52:1745-1754
20. Chang CH, Toh S, Lin JW et al (2011) Cancer risk associated with insulin glargine among adult type 2 diabetes patients-a nationwide cohort study. PLoS One 6:e21368
21. Dejgaard A, Lynggaard H, Rastam J, Krogsgaard Thomsen M (2009) No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 52:2507-2512
22. Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52:2499-2506
23. Rosenstock J, Fonseca V, McGill JB et al (2009) Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 52:1971-1973
24. Mannucci E, Monami M, Balzi D et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33:1997-2003
25. Carstensen B (2010) Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes; 59:1254-1260. Diabetes 59: e17-18; author reply e19-22
26. Edwards KL, Riche DM, Stroup JS et al (2010) Insulin glargine and cancer risk: an opinion statement of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy. Pharmacotherapy 30:955-965
27. Gerstein HC (2010) Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA 303:446-447
28. Hernandez-Diaz S, Adami HO (2010) Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 53:802-808
29. Johnson JA, Gale EA (2010) Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem? Diabetes 59:1129-1131
30. Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374:511-513
31. Simon D (2010) Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues. Diabetologia 53:204-205
32. Smith U, Gale EA (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699-1708
33. Dutch Hospital Data, DBC Information System 1998-2008.Available from www.swov.nl/nl/research/kennisbank/inhoud/90-gegevensbronnen/inhoud/lmr.htm, accessed 1 January 2010
34. Herings R (1993) PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in the Netherlands. Thesis, Department of Pharmacoepidemiology and Pharmacotherapy Utrecht, Utrecht University, 207
35. WHO Collaborating Centre for Drug Statistics Methodology-ATC/DDD Index. Available from www.whocc.no/atc-ddd-index,accessed 1 January 2010
36. WHO (1992) International Statistical Classification of Diseases and Related Health Problems, ninth edition. Available from www.icd9cm.chrisendres. com/, accessed 1January 2010
37. MEB The Dutch Medicines Evaluation Board - Database of Human Medicines. Available from www.cbg-meb.nl/CBG/nl/humane-geneesmiddelen/ geneesmiddeleninformatiebank/default.htm, accessed 1 July2010
38. Stricker BH, Stijnen T (2010) Analysis of individual drug use as a time-varying determinant of exposure in prospective populationbased cohort studies. Eur J Epidemiol 25:245-251
39. Suissa S, Azoulay L, Dell'aniello S, Evans M, Vora J, Pollak M (2011) Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 54:2254-2262
40. Morden N, Liu S, Smith J, Mackenzie T, Skinner J, Korc M (2011) Further exploration of the relationship between insulin glargine and incident cancer-a retrospective cohort study of older Medicare patients. Diabetes Care 34:1965-1971
41. Mayer D, Shukla A, Enzmann H (2008) Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 114:38-44 (Pubitemid 351998750)
42. Mayer D, Chantelau E (2010) Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 116:73-78
43. Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005 (Pubitemid 30349423)
44. Bowker SL, Yasui Y, Veugelers P, Johnson JA (2010) Glucoselowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 53:1631-1637
45. Yang X, Ko GT, So WY et al (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59:1254-1260
46. Rothman K (2002) Epidemiology, an introduction. Oxford University Press, Oxford
47. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846 (Pubitemid 46024990)